AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Feature|Articles|August 13, 2026
- Pharmaceutical Executive: August 2026
- Volume 46
- Issue 6
2026 Emerging Pharma Leaders
Author(s)Mike Hollan
Listen
0:00 / 0:00
From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.
Advertisement
Follow the links below to read about each selection:
(In alphabetical order)
* These five selections were chosen from a pool of nominations evaluated by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “C-suite” functions.
Articles in this issue
about 1 month ago
Pharmaceutical Executive: August 2026 Interactive Digital Editionabout 1 month ago
More Than Titlesabout 2 months ago
2026 Pharm Exec Top 50 Companiesabout 2 months ago
From Value Imperative to Operating Reality: Rethinking Trust in Pharmaabout 2 months ago
Making the Smart Career Movesabout 2 months ago
Two Decades of Technology Transformation in Pharmaabout 2 months ago
Finding the Universal Truth in a Drug's Storyabout 2 months ago
Preventing Cardiovascular Disease Through Mission-Driven Leadershipabout 2 months ago
What C-Suite Readiness Really RequiresAdvertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz
2
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
3
Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch
4
Your Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warning
5